{
    "clinical_study": {
        "@rank": "28263", 
        "arm_group": [
            {
                "arm_group_label": "RO5285119 + risperidone", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "RO5285119 + placebo", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Placebo + risperidone", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Placebo +placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This single-center, randomized, double-blind, two-period crossover study will evaluate the\n      safety, tolerability, pharmacokinetics and pharmacodynamic effects of the combination of\n      multiple doses of RO5285119 with a single dose of risperidone in healthy volunteers.\n      Subjects will be randomized to one of 4 treatment sequences of two periods to receive\n      multiple doses of RO5285119 plus a single dose of risperidone or risperidone placebo or\n      multiple doses of RO5285119 placebo plus a single dose of risperidone or risperidone\n      placebo, with a washout period of approximately 3 weeks between treatment periods.\n      Anticipated time on study is up to 12 weeks (from screening through study completion)."
        }, 
        "brief_title": "A Study of the Combination of Multiple Doses of RO5285119 With a Single Dose of Risperidone in Healthy Volunteers", 
        "completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteer", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male and female adults, 18 - 50 years of age inclusive Healthy status is\n             defined by absence of evidence of any active or chronic disease following detailed\n             medical and surgical history and a physical examination including vital signs,\n             12-lead ECG, hematology, blood chemistry, serology and urinalysis\n\n          -  Body mass index (BMI) 18 to 30 kg/m2 inclusive\n\n          -  Women have to be postmenopausal or surgically sterile\n\n          -  Male subjects must use a barrier method of contraception for the duration of the\n             study and for 3 months after last dosing\n\n        Exclusion Criteria:\n\n          -  Suspicion of regular consumption of drug of abuse, or history of drug or alcohol\n             abuse\n\n          -  Positive for hepatitis B, hepatitis C or HIV infection\n\n          -  History of clinically significant hypersensitivity or allergic reactions\n\n          -  Disorders of the central nervous system, including psychiatric disorders, behavioural\n             disturbances, cerebrovascular events, depression, bipolar disorder, migraine,\n             Parkinson\n\n          -  Regular smoker (>5 cigarettes, >3 pipe-fulls, >3 cigars per day)\n\n          -  Administration of an investigational drug or device within 3 months prior to first\n             dosing\n\n               -  Hypersensitivity to risperidone or any of its excipients\n\n          -  Any other known contraindications to risperidone as stated in the SmPC"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 15, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01708616", 
            "org_study_id": "BP28318", 
            "secondary_id": "2012-003231-31"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "RO5285119 + risperidone", 
                    "RO5285119 + placebo"
                ], 
                "description": "multiple doses", 
                "intervention_name": "RO5285119", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "RO5285119 + risperidone", 
                    "Placebo + risperidone"
                ], 
                "description": "single dose", 
                "intervention_name": "risperidone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Placebo + risperidone", 
                    "Placebo +placebo"
                ], 
                "description": "multiple doses", 
                "intervention_name": "RO5285119 placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "RO5285119 + placebo", 
                    "Placebo +placebo"
                ], 
                "description": "single dose", 
                "intervention_name": "risperidone placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Risperidone"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rennes", 
                    "country": "France", 
                    "zip": "35042"
                }
            }
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Single-center, Randomized, Double-blind, Two-period Crossover Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of the Combination of Multiple Doses of RO5285119 With a Single Dose of Risperidone in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "France: Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 (ANSM)"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetics of single dose risperidone in combination with multiple doses of RO5285119: Maximum plasma concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose to 24 hours post-dose"
            }, 
            {
                "measure": "Pharmacokinetics of single dose risperidone in combination with multiple doses of RO5285119: Area under the concentration-time curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose to 24 hours post-dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01708616"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 12 weeks"
            }, 
            {
                "measure": "Pharmacodynamic markers for risperidone: Prolactin levels", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose to 6 hours post-dose"
            }, 
            {
                "measure": "Pharmacodynamic assessments for risperidone: Level of sedation", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose to 24 hours post-dose"
            }, 
            {
                "measure": "Pharmacokinetics of RO5285119 in combination with single dose risperidone: Maximum plasma concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 to Day 18"
            }, 
            {
                "measure": "Pharmacokinetics of RO5285119 in combination with single dose risperidone: Area under the concentration-time curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Day1 to Day 18"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}